» Articles » PMID: 16631222

Functional Impact of HIV Coreceptor-binding Site Mutations

Overview
Journal Virology
Specialty Microbiology
Date 2006 Apr 25
PMID 16631222
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The bridging sheet region of the gp120 subunit of the HIV-1 Env protein interacts with the major virus coreceptors, CCR5 and CXCR4. We examined the impact of mutations in and adjacent to the bridging sheet region of an X4 tropic HIV-1 on membrane fusion and entry inhibitor susceptibility. When the V3-loop of this Env was changed so that CCR5 was used, the effects of these same mutations on CCR5 use were assayed as well. We found that coreceptor-binding site mutations had greater effects on CXCR4-mediated fusion and infection than when CCR5 was used as a coreceptor, perhaps related to differences in coreceptor affinity. The mutations also reduced use of the alternative coreceptors CCR3 and CCR8 to varying degrees, indicating that the bridging sheet region is important for the efficient utilization of both major and minor HIV coreceptors. As seen before with a primary R5 virus strain, bridging sheet mutations increased susceptibility to the CCR5 inhibitor TAK-779, which correlated with CCR5 binding efficiency. Bridging sheet mutations also conferred increased susceptibility to the CXCR4 ligand AMD-3100 in the context of the X4 tropic Env. However, these mutations had little effect on the rate of membrane fusion and little effect on susceptibility to enfuvirtide, a membrane fusion inhibitor whose activity is dependent in part on the rate of Env-mediated membrane fusion. Thus, mutations that reduce coreceptor binding and enhance susceptibility to coreceptor inhibitors can affect fusion and enfuvirtide susceptibility in an Env context-dependent manner.

Citing Articles

phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study.

Gracias S, El Yaalaoui I, Visseaux B, Charpentier C, Descamps D, Martin C Microbiol Spectr. 2024; 12(7):e0389523.

PMID: 38809042 PMC: 11218461. DOI: 10.1128/spectrum.03895-23.


Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1.

Cheedarla N, Sundaramurthi J, Hemalatha B, Anangi B, Nesakumar M, Ashokkumar M AIDS Res Hum Retroviruses. 2018; 35(2):169-184.

PMID: 30328700 PMC: 6909397. DOI: 10.1089/AID.2018.0224.


Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism.

Scinto H, Gupta S, Thorat S, Mukhtar M, Griffiths A, Delgado J J Virol. 2018; 92(14).

PMID: 29743361 PMC: 6026739. DOI: 10.1128/JVI.02222-17.


Screening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors.

Giroud C, Du Y, Marin M, Min Q, Jui N, Fu H Assay Drug Dev Technol. 2017; 15(2):53-63.

PMID: 28322598 PMC: 5367911. DOI: 10.1089/adt.2017.777.


Biased small-molecule ligands for selective inhibition of HIV-1 cell entry via CCR5.

Berg C, Spiess K, Luttichau H, Rosenkilde M Pharmacol Res Perspect. 2017; 4(6):e00262.

PMID: 28097000 PMC: 5226280. DOI: 10.1002/prp2.262.